Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron ...

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.

According to Benzinga Pro, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 6.13 ...

Over 100 students showcased 76 STEMI projects at the Eskom Expo East London regional fair, with the engineering category ...

Sanofi (SNY) halts shipments of cholesterol drug Praluent developed with Regeneron (REGN) due to availability issues. Read ...